SEARCH

SEARCH BY CITATION

References

  • 1
    Hopkins RJ, Girardi LS, Turney EA. Relationship between H. pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996; 110: 1244 52.
  • 2
    De Boer WA & Tytgat GNJ. 90% Cure: which anti-Helicobacter therapy can achieve this treatment goal? Am J Gastroenterol 1995; 90: 1381 2.
  • 3
    Anon. Current European concepts in the management of H. pylori infection. The Maastricht consensus report. Gut 1997; 41: 8 13.
  • 4
    Lee J & O’Morain C. Consensus or confusion: a review of existing national guidelines on Helicobacter pylori related disease. Eur J Gastroenterol Hepatol 1997; 9: 527 31.
  • 5
    Howden CW & Hunt RH. Guidelines for the management of Helicobacter pylori infection. Am J Gastroenterol 1998; 93: 2330 8.
    Direct Link:
  • 6
    Van Der Hulst RWM, Keller JJ, Rauws EAJ, Tytgat GNJ. Treatment of Helicobacter pylori infection in humans: a review of the world literature. Helicobacter 1996; 1: 6 19.
  • 7
    Treiber G. The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis. Am J Gastroenterol 1996; 91: 246 57.
  • 8
    De Boer WA & Tytgat GNJ. How to treat H. pylori infection. Should treatment strategies be based on testing bacterial susceptibility? A personal viewpoint. Eur J Gastroenterol Hepatol 1996; 8: 709 16.
  • 9
    De Boer WA. Bismuth triple therapy: still a very important drug regimen for curing Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1999; 11: 697 700.
  • 10
    Chiba N & Hunt RH. Bismuth, metronidazole and tetracycline and acid suppression in H. pylori eradication: a meta-analysis. Gut 1996; 39(Suppl. 2): A36 7(Abstract).
  • 11
    Hosking SW, Ling TKW, Yung MY, et al. Randomised controlled trial of short term treatment to eradicate H. pylori in patients with duodenal ulcer. Br Med J 1992; 305: 502 4.
  • 12
    Hosking SW, Ling TKW, Chung SCS, et al. Duodenal ulcer healing by eradication of H. pylori without anti-acid treatment. Randomised controlled trial. Lancet 1994; 343: 508 10.
  • 13
    De Boer WA, Driessen WMM, Jansz AR, Tytgat GNJ. Effect of acid suppression on efficacy of treatment for Helicobacter pylori. Lancet 1995; 345: 817 20.
  • 14
    De Boer WA, Driessen WMM, Jansz AR, Tytgat GNJ. Quadruple therapy compared with dual therapy for eradication of Helicobacter pylori in ulcer patients. Eur J Gastroenterol Hepatol 1995; 7: 1189 94.
  • 15
    Borody TJ, Andrews P, Shortis NP, Hyland I. Seven day therapy for Helicobacter Pylori. Gastroenterology 1995; 108: A62A62(Abstract).
  • 16
    Sung JJY, Leung VKS, Chung SCS, et al. Triple therapy with sucralfate, tetracycline and metronidazole for Helicobacter associated duodenal ulcers. Am J Gastroenterol 1995; 90: 1424 7.
  • 17
    De Boer WA, Etten RJXM, Lai JYL, Schneeberger PM, Van De Wouw BAM, Driessen WMM. Effectiveness of quadruple therapy using lansoprazole instead of omeprazole in curing Helicobacter pylori infection. Helicobacter 1996; 1: 145 50.
  • 18
    Vautier G & Scott BB. A one week quadruple eradication regimen for Helicobacter pylori in routine clinical practice. Aliment Pharmacol Ther 1997; 11: 107 8.
  • 19
    Bolin TD, Korman MG, Engelman JL, Nicholson FB. Lansoprazole and bismuth triple therapy in the eradication of Helicobacter pylori. Gastroenterology 1997; 112: A76A76(Abstract).
  • 20
    Kung NNS, Sung JJY, Yuen NWF, et al. Anti-Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy. Am J Gastroenterol 1997; 92: 438 41.
  • 21
    Chan FKL, Yung MY, Ling TKW, Leung WK, Chung SCS. What is the true impact of metronidazole resistance on the efficacy of bismuth triple therapy? Gut 1998; 43(Suppl. 2): A84A84(Abstract).
  • 22
    De Boer WA & Borody TJ. Towards monotherapy for Helicobacter pylori infection: first results with a single triple capsule. Gastroenterology 1998; 114: A98A98(Abstract).
  • 23
    Van Zwet AA, De Boer WA, Schneeberger PM, Weel J, Jansz AR, Thys JC. Prevalence of primary Helicobacter pylori resistance to metronidazole and clarithromycin in the Netherlands. Eur J Clin Microb Infect Dis 1996; 15: 861 4.
  • 24
    Van De Wouw BAM, De Boer WA, Hermsen HWEM, Valkenburg JGM, Geuskens LM. Usefulness of the 14C urea breath test as a semi quantitative monitoring instrument after therapy for Helicobacter pylori infection. Scand J Gastroenterol 1997; 32: 112 7.
  • 25
    Van De Wouw BAM, Lahey RJF, Schneeberger PM, De Boer WA. IgG serology at 6 months is a reliable predictor for cure of H. pylori infection. Gastroenterology 1999; 116: A357A357(Abstract).
  • 26
    De Boer WA, Thys JC, Borody TJ, Graham DY, O’Morain C, Tytgat GNJ. Proposal for use of a standard side effect scoring system in studies exploring H. pylori treatment regimens. Eur J Gastroenterol Hepatol 1996; 8: 641 3.
  • 27
    Salman-Roghani H, Massarrat S, Pahlewanzadeh MR, Dashti M. Effect of two different doses of metronidazole and tetracycline in bismuth triple therapy on eradication of Helicobacter pylori and its resistant strains. Eur J Gastroenterol Hepatol 1999; 11: 709 12.
  • 28
    Schmid CH, Ross SD, Whiting GW, Cory D, Chalmers TC. Omeprazole plus antibiotics in the eradication of H. pylori infection: a meta-regression. Gut 1996; 39(Suppl. 2): A37A37(Abstract).
  • 29
    Houben MHMG, Schraffordt Koops HW, Rauws EAJ, et al. Efficacy of PPI-triple therapy in Helicobacter pylori positive patients with peptic ulcer disease versus patients with functional dyspepsia. Gastroenterology 1999; 116: A190A190(Abstract).
  • 30
    Van Doorn LJ, Quint W, Schneeberger PM, Tytgat GMJ, De Boer WA. The only good Helicobacter is a dead Helicobacter. Lancet 1997; 350: 71 2.
  • 31
    Borda F, Martinez A, Echarri A, Jimenez J, Rodriguez C, Jara C. Clinical practice results of quadruple treatment in Helicobacter pylori eradication failure with OCA-7. Gut 1998; 43(Suppl. 2): A81A81(Abstract).
  • 32
    Huelin Benitez J, Jimenez Perez M, Duran Campos A, et al. Quadruple therapy with omeprazole, tetracycline, metronidazole and bismuth as a second option after failure of a first eradication therapy. Gut 1998; 43(Suppl. 2): A86A86(Abstract).